The Gut Microbiota and Associated Metabolites Are Altered in Sleep Disorder of Children With Autism Spectrum Disorders

Hua, Xueying; Zhu, Jiang; Yang, Ting; Guo, Min; Li, Qiu; Chen, Jie; Li, Tingyu

doi:10.3389/fpsyt.2020.00855

Cited by 73 publications

(65 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are currently a large number of studies on the overall sleep status and autism symptoms of ASD, so we do not separately analyze and discuss it, but focus the research on different dimensions. For this study, it is the four dimensions of with the highest prevalence [ 44 – 46 ].…”

Section: Discussionmentioning

confidence: 99%

Sleep problems in children with autism spectrum disorder: a multicenter survey

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background High prevalence of sleep problems have been reported in children with Autism Spectrum Disorder (ASD). This study aims to investigate the sleep conditions of ASD children in China, and explore the relationship between the common sleep problems and core symptoms and developmental levels. Methods Using a cross-sectional design, we included 2 to 7-year-old children from 13 cities in China: 1310 with ASD and 1158 with typically-developing (TD) children. The neurodevelopmental level was evaluated with the revised Children Neuropsychological and Behavior Scale (CNBS-R2016). ASD were diagnosed with DSM-5 and Child Autism Rating Scale (CARS). the Social Responsiveness Scale (SRS), the Autism Behavior Checklist (ABC) and the communication warning behavior sub-scale in CNBS-R2016 valued autism behaviors. The children’ s sleep habits questionnaire (CSHQ) assessed sleep conditions. Results The prevalence of sleep disorders in ASD children was significantly higher than that in TD (67.4% vs. 51%, p < 0.01), and among them the four dimensions with the highest prevalence of sleep problems were bedtime resistance (25.6%), sleep anxiety (22.7%), sleep onset delay (17.9%) and daytime sleepiness (14.7%). ASD children with sleep onset delay or sleep anxiety had higher ABC, SRS scores and higher scores on communication warning behavior with sleep anxiety, with daytime sleepiness had higher ABC, SRS and CARS scores, and with bedtime resistance had higher SRS total scores. Differences in the neurodevelopmental level were not significant. Conclusion Children with ASD have a higher prevalence of sleep problems. Bedtime resistance, anxiety, sleep onset delay and daytime sleepiness may be related to the core symptoms, but not be related to the developmental level in ASD children. In the clinic, sleep assessment should be included in the routine of ASD visits, and during the intervention, sleep hygiene education is as important as the treatment of biological factors. Trial registration The study was approved by the ethics committee of the Children’s Hospital of Chongqing Medical University, Approval Number: (2018) IRB (STUDY) NO. 121, and registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2000031194).

show abstract

Section: Discussionmentioning

confidence: 99%

Sleep problems in children with autism spectrum disorder: a multicenter survey

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The importance of the gut-brain axis has been widely described and a growing body of evidence highlights a role for alterations in the GM in the pathophysiology of many neurologic and neuropsychiatric diseases, including autism spectrum disorder (ASD). Hua and co-workers reported a significantly reduction in the abundances of butyrate-producing bacteria Faecalibacterium and Agathobacter in ASD children [ 62 ]. To further emphasize this link recent work has shown that GM alterations leads to have a significant impact on amygdala development in infancy, modulating the development of the frontal cortex and other brain regions [ 63 ].…”

Section: Butyratementioning

confidence: 99%

The Protective Role of Butyrate against Obesity and Obesity-Related Diseases

et al. 2021

View full text Add to dashboard Cite

Worldwide obesity is a public health concern that has reached pandemic levels. Obesity is the major predisposing factor to comorbidities, including type 2 diabetes, cardiovascular diseases, dyslipidemia, and non-alcoholic fatty liver disease. The common forms of obesity are multifactorial and derive from a complex interplay of environmental changes and the individual genetic predisposition. Increasing evidence suggest a pivotal role played by alterations of gut microbiota (GM) that could represent the causative link between environmental factors and onset of obesity. The beneficial effects of GM are mainly mediated by the secretion of various metabolites. Short-chain fatty acids (SCFAs) acetate, propionate and butyrate are small organic metabolites produced by fermentation of dietary fibers and resistant starch with vast beneficial effects in energy metabolism, intestinal homeostasis and immune responses regulation. An aberrant production of SCFAs has emerged in obesity and metabolic diseases. Among SCFAs, butyrate emerged because it might have a potential in alleviating obesity and related comorbidities. Here we reviewed the preclinical and clinical data that contribute to explain the role of butyrate in this context, highlighting its crucial contribute in the diet-GM-host health axis.

show abstract

“…In a Chinese population of 120 children with ASD, Hua et al [ 191 ] explored the differences in the composition of the gut microbiome and its metabolites between those patients who suffered from sleep disorders ( n = 60) and those without sleep problems ( n = 60). Sleep disorders were assessed through the Children Sleep Habits Questionnaire (CSHQ).…”

Section: Microbiota–gut–brain Axis and Attention-deficit And/or Hymentioning

confidence: 99%

Current Evidence on the Role of the Gut Microbiome in ADHD Pathophysiology and Therapeutic Implications

et al. 2021

View full text Add to dashboard Cite

Studies suggest that the bidirectional relationship existent between the gut microbiome (GM) and the central nervous system (CNS), or so-called the microbiome–gut–brain axis (MGBA), is involved in diverse neuropsychiatric diseases in children and adults. In pediatric age, most studies have focused on patients with autism. However, evidence of the role played by the MGBA in attention deficit/hyperactivity disorder (ADHD), the most common neurodevelopmental disorder in childhood, is still scanty and heterogeneous. This review aims to provide the current evidence on the functioning of the MGBA in pediatric patients with ADHD and the specific role of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in this interaction, as well as the potential of the GM as a therapeutic target for ADHD. We will explore: (1) the diverse communication pathways between the GM and the CNS; (2) changes in the GM composition in children and adolescents with ADHD and association with ADHD pathophysiology; (3) influence of the GM on the ω-3 PUFA imbalance characteristically found in ADHD; (4) interaction between the GM and circadian rhythm regulation, as sleep disorders are frequently comorbid with ADHD; (5) finally, we will evaluate the most recent studies on the use of probiotics in pediatric patients with ADHD.

show abstract

The Gut Microbiota and Associated Metabolites Are Altered in Sleep Disorder of Children With Autism Spectrum Disorders

Cited by 73 publications

References 49 publications

Sleep problems in children with autism spectrum disorder: a multicenter survey

Sleep problems in children with autism spectrum disorder: a multicenter survey

The Protective Role of Butyrate against Obesity and Obesity-Related Diseases

Current Evidence on the Role of the Gut Microbiome in ADHD Pathophysiology and Therapeutic Implications

Contact Info

Product

Resources

About